A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy

Summary

This was a randomized, double-blind, placebo-controlled, 2-arm, 1-year study of participants who completed the EXCELS study (NCT00252135) and had received long-term treatment with Xolair. In addition, participants who did not participate in the EXCELS study but received long-term (\~5 years) treatment with Xolair were allowed to enter the study.

Timeline

Start

2010-05

Primary completion

2013-08

Completion

2013-08

Outcome

Met primary endpoint

registry Mean Difference (Final Values) 19.3 (95% CI 5.0 to 33.6) NCT01125748 ↗

Drugs

Indications